DCGI authorised Akums Perampanel oral Suspension for Treatment of Epilepsy

Akums announced the approval of perampanel oral suspension by the Drug Controller General of India (DCGI). The perampanel oral suspension is a bioequivalent formulation to the US FDA-approved FYCOMPA (perampanel) oral suspension. This approval allows perampanel oral suspension to serve as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalised seizures, as well as primary generalised tonic-clonic (PGTC) seizures in patients with epilepsy aged 12 years and older in the country.

According to a report by the World Health Organisation (WHO) around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. An estimated five million people are diagnosed with epilepsy every year. India has more than 10 million patients with epilepsy, ie, 20 per cent out of 50 million worldwide. "We are excited about the approval of perampanel oral suspension, as it provides another treatment option for patients with epilepsy who may have difficulty swallowing tablets or prefer liquids," said Sanjeev Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals.

Sandeep Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals, explained, "Perampanel represents an important new option for the treatment of partial-onset epilepsy, and it holds the potential to play a key role in improving seizure management, particularly in poorly controlled adults and adolescents." The newly approved perampanel oral suspension formulation is now available in 100 ml bottles, with a strength of 0.5mg/ml. The packaging includes a convenient oral dosing applicator ensuring accurate dosage administration and enhancing patient compliance.